Document is current

Article History

Received: 12 April 2022

Accepted: 5 January 2023

First Online: 25 January 2023

Declarations

:

: The imaging analysis was approved by the Aachen RWTH institutional review board (No. EK 260/19). According to Danish National Legislation, the Danish Patient Safety Authority waived informed consent for retrospective studies (approval 31-1521-110).

: Not applicable.

: Akshayaa Vaidyanathan, Flore Belmans, Fabio Bottari are salaried employees of Radiomics.

: Philippe Lambin reports, within and outside the submitted work, grants/sponsored research agreements from Radiomics SA, ptTheragnostic/DNAmito, and Health Innovation Ventures. He received an advisor/presenter fee and/or reimbursement of travel costs/consultancy fee and/or in kind manpower contribution from Radiomics SA, BHV, Merck, Varian, Elekta, ptTheragnostic, BMS and Convert pharmaceuticals. Lambin has minority shares in the companies Radiomics SA, Convert pharmaceuticals, Comunicare, and LivingMed Biotech, and he is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Radiomics SA and one issue patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, three non-patented invention (softwares) licensed to ptTheragnostic/DNAmito, Radiomics SA and Health Innovation Ventures and three non-issues, non-licensed patents on Deep LearningRadiomics and LSRT (N2024482, N2024889, N2024889). He confirms that none of the above entities or funding was involved in the preparation of this paper.

: Henry Woodruff has minority shares in the company Radiomics.

: Felix M. Mottaghy received an advisor fee and reimbursement of travel costs from Radiomics. He reports institutional grants from GE and Nanomab outside the submitted work.

: Mariaelena Occhipinti reports personal fees from Radiomics, outside the submitted work.

: Wim Vos and Sean Walsh have shares in the company Radiomics.

: The rest of co-authors declare no competing interest.